These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31713493)
1. The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population. Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE Curr Mol Pharmacol; 2020; 13(3):233-244. PubMed ID: 31713493 [TBL] [Abstract][Full Text] [Related]
2. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition. Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24. Lau PS; Leong KV; Ong CE; Dong AN; Pan Y Biochem Genet; 2017 Feb; 55(1):48-62. PubMed ID: 27578295 [TBL] [Abstract][Full Text] [Related]
4. Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro. Zhou XY; Hu XX; Li MF; Wang H; Zhang LQ; Hu GX; Cai JP Drug Test Anal; 2018 May; 10(5):807-813. PubMed ID: 29098786 [TBL] [Abstract][Full Text] [Related]
5. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B. Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443 [TBL] [Abstract][Full Text] [Related]
6. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Uehara S; Kawano M; Murayama N; Uno Y; Utoh M; Inoue T; Sasaki E; Yamazaki H Biochem Pharmacol; 2016 Nov; 120():56-62. PubMed ID: 27641812 [TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro. Fang P; He JY; Han AX; Lan T; Dai DP; Cai JP; Hu GX Pharmacology; 2017; 100(1-2):91-97. PubMed ID: 28494448 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory kinetics of fruit components on CYP2C19 activity. Seki H; Akiyoshi T; Imaoka A; Ohtani H Drug Metab Pharmacokinet; 2019 Jun; 34(3):181-186. PubMed ID: 30979536 [TBL] [Abstract][Full Text] [Related]
9. Site-Directed Mutagenesis of Cytochrome P450 2D6 and 2C19 Enzymes: Expression and Spectral Characterization of Naturally Occurring Allelic Variants. Dong AN; Pan Y; Palanisamy UD; Yiap BC; Ahemad N; Ong CE Appl Biochem Biotechnol; 2018 Sep; 186(1):132-144. PubMed ID: 29524040 [TBL] [Abstract][Full Text] [Related]
10. Interactions of omeprazole-based analogues with cytochrome P450 2C19: a computational study. Li J; Du H; Wu Z; Su H; Liu G; Tang Y; Li W Mol Biosyst; 2016 May; 12(6):1913-21. PubMed ID: 27098535 [TBL] [Abstract][Full Text] [Related]
11. Effects of tanshinones from Salvia miltiorrhiza on CYP2C19 activity in human liver microsomes: enzyme kinetic and molecular docking studies. Hu T; Zhou X; Wang L; Or PM; Yeung JH; Kwan YW; Cho CH Chem Biol Interact; 2015 Mar; 230():1-8. PubMed ID: 25686904 [TBL] [Abstract][Full Text] [Related]
12. Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. Hosaka S; Murayama N; Satsukawa M; Uehara S; Shimizu M; Iwasaki K; Iwano S; Uno Y; Yamazaki H Biopharm Drug Dispos; 2015 Dec; 36(9):636-43. PubMed ID: 26348733 [TBL] [Abstract][Full Text] [Related]
13. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355 [TBL] [Abstract][Full Text] [Related]
14. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680 [TBL] [Abstract][Full Text] [Related]
15. In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population. Dai DP; Hu LM; Geng PW; Wang SH; Cai J; Hu GX; Cai JP Xenobiotica; 2015; 45(11):1030-5. PubMed ID: 26153442 [TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Hanioka N; Tsuneto Y; Saito Y; Maekawa K; Sawada J; Narimatsu S Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):388-93. PubMed ID: 18312490 [TBL] [Abstract][Full Text] [Related]
17. Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Uehara S; Uno Y; Inoue T; Kawano M; Shimizu M; Toda A; Utoh M; Sasaki E; Yamazaki H Drug Metab Dispos; 2015 Oct; 43(10):1408-16. PubMed ID: 26228688 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Wang H; Kim RA; Sun D; Gao Y; Wang H; Zhu J; Chen C Xenobiotica; 2011 Sep; 41(9):826-35. PubMed ID: 21692664 [TBL] [Abstract][Full Text] [Related]
19. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Wang JH; Li PQ; Fu QY; Li QX; Cai WW Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410 [TBL] [Abstract][Full Text] [Related]
20. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]